Two alternative approaches to drugging one of the most frequently dysregulated pathways in cancer have recently been gathering momentum in clinical development.
The post Multi-Node PI3K Inhibition for Cancer: Optimizing Efficacy and Safety While Broadening the Patient Population appeared first on MedCity News.
